Similar articles

• Saquinavir: an HIV proteinase inhibitor.

  Bragman K. Bragman K. Adv Exp Med Biol. 1996;394:305-17. doi: 10.1007/978-1-4757-9209-6_28. Adv Exp Med Biol. 1996. PMID: 8815695 Review. No abstract available.
• Development of drug resistance to HIV-1 protease inhibitors.

  Ridky T, Leis J. Ridky T, et al. J Biol Chem. 1995 Dec 15;270(50):29621-3. doi: 10.1074/jbc.270.50.29621. J Biol Chem. 1995. PMID: 8530341 Review. No abstract available.
• Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.

  Nagy K, Young M, Baboonian C, Merson J, Whittle P, Oroszlan S. Nagy K, et al. J Virol. 1994 Feb;68(2):757-65. doi: 10.1128/JVI.68.2.757-765.1994. J Virol. 1994. PMID: 8289379 Free PMC article.
• In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.

  Jacobsen H, Hänggi M, Ott M, Duncan IB, Owen S, Andreoni M, Vella S, Mous J. Jacobsen H, et al. J Infect Dis. 1996 Jun;173(6):1379-87. doi: 10.1093/infdis/173.6.1379. J Infect Dis. 1996. PMID: 8648209
• In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.

  St Clair MH, Pennington KN, Rooney J, Barry DW. St Clair MH, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S83-91. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7552518